Litigation over GlaxoSmithKline’s handling of information about the suicide risk from antidepressant Paxil has turned up some documents that say a lot about why the FDA often seems to be in the dark when problems with drugs surface.
Buried in the documents was a strange exchange between lawyers suing Glaxo over Paxil and attorneys defending the [...]
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment